This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy

Exact Therapeutics


Exact Therapeutics, clinical-stage biopharmaceutical company developing a proprietary ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® significantly amplifies the clinical utility of a wide range of therapeutic agents across a multitude of applications, including oncology (chemotherapy and immunotherapy), neurological conditions, and gene therapy. Exact's primary focus is oncology, followed by CNS. The lead compound is PS101 which is in Phase 1b for liver metastases and a Phase 2 trial in pancreatic cancer is planned for 2H 2024. EXACT Therapeutics was spun out from GE Healthcare in 2012.